After two attempts to get out of a whistleblower case, Pfizer is still on the hook for claims it illegally marketed an anti-fungal medication, Vfend, for off-label use.
U.S. District Judge Barclay Surrick of the Eastern District of Pennsylvania denied Pfizer’s motion to dismiss relators’ Catherine Brown and Bernard Vezeau’s false claims qui tam case against the company.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
